Pharmacological approach to the treatment of long and short QT syndromes
- 18 February 2008
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 118 (1) , 138-151
Abstract
No abstract availableKeywords
This publication has 103 references indexed in Scilit:
- In vivo Effects of Mutant HERG K+ Channel Inhibition by Disopyramide in Patients with a Short QT‐1 Syndrome: A Pilot StudyJournal of Cardiovascular Electrophysiology, 2007
- SCN4B -Encoded Sodium Channel β4 Subunit in Congenital Long-QT SyndromeCirculation, 2007
- Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: Effects of ranolazineHeart Rhythm, 2007
- Loss-of-Function Mutations in the Cardiac Calcium Channel Underlie a New Clinical Entity Characterized by ST-Segment Elevation, Short QT Intervals, and Sudden Cardiac DeathCirculation, 2007
- Short QT syndrome: mechanisms, diagnosis and treatmentNature Clinical Practice Cardiovascular Medicine, 2005
- Epinephrine-Induced QT Interval Prolongation: A Gene-Specific Paradoxical Response in Congenital Long QT SyndromeMayo Clinic Proceedings, 2002
- Influence of the Genotype on the Clinical Course of the Long-QT SyndromeNew England Journal of Medicine, 1998
- Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndromeJACC, 1995
- The long QT syndrome: a prospective international study.Circulation, 1985
- Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval, and sudden deathAmerican Heart Journal, 1957